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Abstract
Mucosal vaccination offers great advantage for inducing protective immune response to prevent viral transmission and
dissemination. Here, we report our findings of a head-to-head comparison of two viral vectors modified vaccinia Ankara
(MVA) and a novel replication-competent modified vaccinia Tian Tan (MVTT) for inducing neutralizing antibodies (Nabs) via
intramuscular and mucosal vaccinations in mice. MVTT is an attenuated variant of the wild-type VTT, which was historically
used as a smallpox vaccine for millions of Chinese people. The spike glycoprotein (S) of SARS-CoV was used as the test
antigen after the S gene was constructed in the identical genomic location of two vectors to generate vaccine candidates
MVTT-S and MVA-S. Using identical doses, MVTT-S induced lower levels (,2-3-fold) of anti- SARS-CoV neutralizing
antibodies (Nabs) than MVA-S through intramuscular inoculation. MVTT-S, however, was capable of inducing consistently
20-to-100-fold higher levels of Nabs than MVA-S when inoculated via either intranasal or intraoral routes. These levels of
MVTT-S-induced Nab responses were substantially (,10-fold) higher than that induced via the intramuscular route in the
same experiments. Moreover, pre-exposure to the wild-type VTT via intranasal or intraoral route impaired the Nab response
via the same routes of MVTT-S vaccination probably due to the pre-existing anti-VTT Nab response. The efficacy of intranasal
or intraoral vaccination, however, was still 20-to-50-fold better than intramuscular inoculation despite the subcutaneous
pre-exposure to wild-type VTT. Our data have implications for people who maintain low levels of anti-VTT Nabs after
historical smallpox vaccination. MVTT is therefore an attractive live viral vector for mucosal vaccination.
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Introduction
Vaccinia virus (VV) provided excellent prophylactic immunity
to variola virus, the causative agent of smallpox, and led to the
eradication of this fatal disease in the world [1–3]. In recent years,
VV has also been successfully used as a live vaccine vector for the
prevention or eradication of other infectious diseases [4,5] because
of its advantage for delivering the expression of foreign antigens in
eukaryotic cells [6–8]. A considerable number of different strains
of VV have been adapted to serve as vaccine vectors such as
NYVAC, NYCBOH, MVA and Tian Tan [6,9–12]. These VV
strains have been engineered to express antigens of herpes simplex
virus, hepatitis B virus, rabies virus, influenza virus, human
immunodeficiency virus (HIV), respiratory syncytial virus (RSV),
severe acute respiratory syndrome coronavirus (SARS-CoV) and
other pathogens, respectively [13–21]. Among them the modified
vaccinia Ankara (MVA) has probably been the most widely studied
vaccinia vector especially due to its excellent safety profile in
humans [17–19,21,22]. MVA vaccine elicited levels of cytotoxic T
lymphocyte (CTL) responses that were comparable to those
induced by replication-competent VV strains [23,24]. Important-
ly, vaccination with MVA protected macaques against pathogenic
monkeypox challenge [23] and MVA-based recombinant vaccines
were able to induce protective immune responses against different
viruses including SARS-CoV, influenza virus and RSV
[14,15,23,25,26]. The immunogenicity of MVA expressing HIV
antigens, however, was not satisfactory as described in recent
human clinical trials [27,28]. Moreover, since MVA requires large
clinical doses (108 PFU or higher) and its propagation needs
special pathogen free (SPF) primary chicken embryo fibroblast
(CEF) cells, it has been a manufacture burden to produce a
sufficient quantity of clinical grade products especially in
developing countries [29,30]. It is therefore necessary to study
other vaccinia-based vaccine vectors.
Some studies have been carried out to investigate whether or
not different vaccinia vectors would offer any advantages
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especially for inducing protective immune responses [31–33]. This
is a critical issue because different VV vectors may harbor distinct
profiles in terms of immune modulation and host virulence
[34],[35–37]. Furthermore, studying mucosal vaccination is also
critical because the major mode of transmission for many viruses
including HIV, SARS-CoV, influenza virus, etc., was through
mucosal surfaces. Conventional replication-competent vaccinia
vectors are considered to be effective in mucosal vaccination but
their safety issues may limit their widespread use in humans [32].
It is, therefore, suggested that attenuated replication-competent
vaccinia vectors should be further studied for mucosal vaccination.
Till now, it remains unknown whether or not our newly developed
replication-competent modified vaccinia Tian Tan (MVTT)
would offer any advantage over the non-replicating MVA for
mucosal vaccination after a test antigen is constructed under an
identical promoter in the same genomic location of two live
vectors, respectively.
Vaccinia Tian Tan (VTT) was historically used as a vaccine for
millions of Chinese people during the worldwide smallpox
prevention campaign, which led to the variola eradication in
China before 1980 [38–40]. Similar to other vaccinia strains, VTT
is a member of the orthopoxvirus genus. Although there is no
historical report on the safety profile of VTT in humans, it has
been suggested that VTT likely exhibits good immunogenicity,
moderate reactogenicity, and relatively mild complications
[11,12]. A recent study suggested that the intranasal delivery of
a VTT-based vaccine, when used in combination with a DNA,
induced strong HIV-specific immune responses [20]. The safety
profile of this particular vaccine for mucosal use was not
mentioned in the publication. We however demonstrated that
the unmodified VTT retains its virulence and pathogencity in
animal studies especially after intranasal administration [38]. Our
data indicated that VTT should be modified to be an intranasal
vaccination vector [38]. We have since generated modified
vaccinia Tian Tan (MVTT) strains by attenuating the virulence
of VTT through viral genomic engineering and clonal selection
[11].
Since the Merck’s CTL-oriented HIV vaccine has recently
failed in clinical trials, it becomes desirable to identify an effective
live vector for eliciting neutralizing antibodies (Nabs). Here, we
studied the potential of our MVTT as a vaccine vector for
inducing Nabs. Specifically, we report findings on a head-to-head
comparison study between MVA and MVTT vectors for mucosal
vaccination. The major uniqueness of MVTT is that it is an
attenuated yet replication-competent strain as tested in mamma-
lian cells. The spike glycoprotein (S) of SARS-CoV was used as the
test antigen after its gene was constructed in the identical genomic
location of two live vectors to generate vaccine candidates MVTT-
S and MVA-S [14,41]. By evaluating the specific neutralizing
antibody (Nab) response against SARS-CoV, we determine the
immunogenicity profiles of two distinct live vaccinia vector systems
in vivo.
Materials and Methods
Virus and vector
The background of the parental vaccinia Tian Tan has been
described in our previous publications [11,38]. A modified dual-
promoter insertion vector, pZCxz was constructed to target the
genomic region of VTT, which corresponds to the Del III region
of MVA [14]. pZCxz contains two promoters namely pSYN and
pH 5, which are both vaccinia virus-specific early/later promoters.
Using pZCxz, S gene and reporter green fluorescent protein (GFP)
gene were incorporated into the genome of VTT to construct the
recombinant vaccinia virus MVTT-S using a homologous
recombination method in African green monkey kidney (Vero)
cells (Fig. 1). The virus was purified through consecutive plaque
selection using GFP as a surrogate marker under a fluorescence
microscope. The stability of S in MVTT was determined by
double-staining S protein and vaccinia specific antigens for 50 foci
of the ninth passaged viral stock, which is similar to a technique we
recently published [11]. Using similar techniques, MVA-S was
constructed by inserting S gene into the Del III region of MVA
genome as we previously described [14].
Immunohistochemistry and Western blot assays
An immunohistochemistry assay was developed for the
detection of SARS-CoV S glycoprotein expressed on cell
surface. Briefly, Vero cells were grown in 35-mm culture dishes
to reach 80% confluence and were subsequently infected with
MVTT-S at a multiplicity of infection (m.o.i.) of 0.01. After viral
absorption for 90 min, cells were washed three times with
culture medium and then incubated at 37uC for another
24 hours (h) to 48 h before immunostaining. After the
incubation, cells were fixed with a cold 1:1 solution of
methanol/acetone for five min and then incubated for 1 h at
room temperature with a rabbit anti-S serum diluted (1:80) in
phosphate buffered saline (PBS) containing 2% fetal bovine
serum (FBS). Cells were washed and then incubated for 1 h at
room temperature with 1:1500 diluted Protein-A conjugated to
horseradish peroxidase (Zhongshan Biotech, Beijing, China).
After wash, the color was developed by incubation for 30 min
with the substrate solution consisting of 10 ml of 30% H2O2 and
0.2 ml of an ethanol saturated dianishidine (Sigma, St. Louis,
MO, USA) solution in 10 ml of PBS [11,38]. For Western blot
analysis, cells were infected with vaccinia virus at a multiplicity
of infection (MOI) of 0.1. 48 h after transfection, cells were
lysed on ice for 30 minutes in 100 mL of lysis buffer (50 mM of
Tris-HCl [pH 8.0]; 137 mM of NaCl; 2 mM of ethylenedi-
aminetetraacetic acid [EDTA]; 0.5% NP-40; 10% glycerol; and
1 mg/mL each of pepstatin, leupeptin, and pefabloc), cleared of
lysate (14,000 rpm for 10 minutes at 4uC), boiled at 100uC for
10 minutes, and run on 10% sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis (Invitrogen, Carlsbad, CA, USA).
After proteins were transferred to polyvinylidene difluoride
membrane (Invitrogen), blots were blocked in 5% milk and
0.5% BSA in PBS; washed; and incubated with rabbit anti-S
(1:100 ratio) polyclonal antibodies. The blots were washed and
incubated with 1:4,000 diluted protein-G horseradish peroxi-
dase (HRP) conjugate (Bio-Rad, Hercules, CA, USA). Immu-
nofluorescence was measured with the enhanced chemolumi-
nescence (ECL) plus kit (Amersham Biosciences, Piscataway, NJ,
USA).
Preparation of viral stocks and viral virulence test
VTT and MVTT-S viral stocks were propagated in Vero cells
and then purified by centrifugation through a 36% sucrose
cushion. MVA-S stock was prepared and purified using chicken
embryo fibroblast (CEF) cells according to a procedure described
previously [14]. Both viral stocks were titrated simultaneously in
CEF by a plaque forming assay using crystal violet staining or
counting the plaques with GFP expression.
To determine the viral virulence in vivo, two groups of six-week
old mice were inoculated with 105 and 106 PFU of MVTT-S via
the i.n. route, respectively. Each group had six mice. The viral
virulence was subsequently determined by the daily measurement
of animal body weight change for a period of 31 days.
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Immunization of animals
For dose escalation study, groups of three six-week-old female
BALB/c mice were immunized by intramuscular (i.m.) injection
of MVTT-S or MVA-S at weeks 0 and 3. Each group of mice
was inoculated with one of 104, 105 and 106 PFU of either
viruses, or a saline control. To determine the best route of
vaccination, a sub-optimal dose (105 PFU) was used for each
group of three BALB/c mice (6-week-old) at weeks 0 and 3. The
vaccination routes included intranasal (i.n.), intraoral (i.o.),
intrarectal (i.r.), intradermal (i.d.), subcutaneous (s.c.) and
intraperitoneal (i.p.) inoculations. For mucosal vaccination study,
groups of 3 BALB/c mice (6-week-old) were immunized with 105
PFU of each virus at weeks 0 and 3 via i.m., i.n., i.o., i.r. routes.
The vaccinated mice were sacrificed two weeks after the second
injection and their blood samples were used for analysis. The
animal experimental protocols were approved by institutional
animal ethic committee and followed the national guidelines for
the use of animals in scientific research.
Pre-existing immunity to VTT
For the experiment of evaluating whether the pre-exposure to
VTT would interfere with the immunogenicity of MVTT-S,
groups of six-week-old BALB/c mice were immunized by the s.c.
injection of 106 PFU VTT at day 0. These mice were kept for six
months and then were inoculated with 106 PFU MVTT-S or
MVA-S twice at one month interval via i.m.; s.c.; i.n.; i.o. routes,
respectively. Sera were collected two weeks after each inoculation
for analysis.
In parallel, as placebo controls, other groups of six-week-old
BALB/c mice were immunized by the s.c. injection of PBS at day
0. These mice were kept for six months and then were inoculated
with 106 PFU MVTT-S or 106 PFU MVA-S or PBS twice at one
month interval via i.m.; s.c.; i.n.; i.o. routes, respectively. Sera were
collected two weeks after each inoculation for analysis.
Neutralization assay
A pseudovirus-based neutralization assay was established to
determine the humoral immune responses against SARS-CoV
[14]. The pseudotype virus was generated by co-transfecting 293T
cells with two plasmids pcDNA-Sopt9 and pNL4-3Lu-
c+Env2Vpr2 carrying the optimized S gene and a human
immunodeficiency virus type 1 backbone, respectively, as we
previously described [14]. The neutralizing activity of heat-
inactivated sera (56uC, 30 min) was determined by mixing 10 ng
of pseudotype virus (in 30 ml) with diluted serum (in 30 ml) at 37uC
for 1 h. After neutralization, the mixture was combined with
16 ng polybrene (in 40 ml medium) and added to HEK293T-
ACE2 cells (10,000 cells per well in 100 ml). Cells were washed
with PBS and lysed (16 Cell Culture Lysis Reagent; Promega,
Madison, WI, USA) 56–72 h after infection. Luciferase activity
was measured and the percentage of neutralization was calculated.
The assay for vaccinia neutralization was based on a previous
publication using the fluorescence-activated cell sorting (FACS)
analysis [42]. For this assay, a VTT-based recombinant virus was
constructed to express the green fluoresces protein (GFP) gene.
Results
Design and characterization of a recombinant MVTT that
expresses the SARS-CoV spike glycoprotein
We have previously generated a MVA-based vaccine, MVA-S,
which was able to prevent SARS-CoV infection in Chinese rhesus
monkeys [14]. In order to make a reasonable comparison between
MVA and MVTT as live vaccine vectors, we used the same
Figure 1. The schematic representation of MVTT-S construction and the expression of the S-glycoprotein in cells infected with
MVTT-S. (A) The S gene of SARS-CoV was introduced, together with GFP gene, each under a separate promoter, into the genome of MVTT. The
restriction enzymes Bam HI and Xho I were used for constructing MVTT-S. The insertion region corresponds to the Del III region of MVA. (B) The S-
glycoprotein was detected on Vero cells infected with MVTT-S (left image) using a rabbit anti-S specific antibody in an immunohistochemical staining
assay. No S-glycoprotein expression was detected on Vero cells infected with the wild-type VTT (right image). (C) The comparable level of S-
glycoprotein expression was detected in CEF cells infected with 16106 PFU of either MVTT-S (lane 2) or MVA-S (lane 3) using the Western blot assay.
Uninfected CEF was included as a negative control (lane 1).
doi:10.1371/journal.pone.0004180.g001
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strategy for the construction of MVA-S to generate a MVTT-
based vaccine. A modified shuttle vector pZCxz was constructed
to target the S gene into the MVTT genome in a location which
corresponds to the Del III region of MVA-S (Fig. 1A). This
shuttle vector contains dual promoters which allow the
simultaneous expression of two target genes. Within this vector,
the S gene of SARS-CoV was constructed under the strong
synthetic promoter pSYN, whereas a reporter GFP gene was
under a separate relatively weaker promoter pH 5 (Fig. 1A).
Since both genes were included within the same insertion frame,
the GFP served as a surrogate marker for the selection of
recombinant VTT carrying the S gene. Using this technique, we
were able to generate and to purify the recombinant virus
MVTT-S. The positive plaque was selected under a fluorescence
microscope and subsequently confirmed by an immunohisto-
chemical assay using an S glycoprotein specific antibody (Fig. 1B,
left image). Moreover, the S protein was also detected by a rabbit
antibody bound to the N-terminal 400 amino acids of the protein
in a Western blot analysis. The S protein appeared at the
position above 170 kDa, which was consistent to our previous
observation (Fig. 1C) [14]. Comparable of levels of S-glycopro-
tein expression were detected in CEF cells using an identical
dose of viral inoculation (Fig. 1C). In addition, MVTT-S was
passaged on Vero cells nine times. By evaluating 50 foci after the
9th passage, we found that 100% of the foci expressed both S
glycoprotein and vaccinia proteins. These passages, therefore,
did not lead to the loss of S glycoprotein expression, indicating
that MVTT-S is likely genetically stable.
Attenuated phenotype of MVTT-S in mice
Considering that the insertion of foreign gene products might
alter the virulence of MVTT, we have evaluated the in vivo toxicity
of MVTT-S in animals. The inbred BALB/c mouse was chosen
for the assessment of MVTT-S virulence as we previously
described [11,38]. The data collected from the 106 PFU group
were presented in Figure 2. Two independent experiments were
conducted with consistent results obtained. None of the mice died
during the experiment period. Furthermore, mice infected with
MVTT-S did not show signs of weight loss (Fig. 2). The body
weight change in mice infected with MVTT-S was comparable
with the control mice. These results suggest that MVTT-S likely
retains an attenuated phenotype and is likely safe for intranasal
vaccination.
MVA-S induces slightly higher levels of Nab response
than MVTT-S via the i.m. route of inoculation
As described previously, a pseudotype-based neutralization
assay was established to characterize the immune sera generated
in mice [14]. The major advantage of this assay is the
elimination of using live SARS-CoV in the traditional neutral-
ization assay. We used this assay to measure the serum
neutralizing activity in animals immunized with MVA-S and
MVTT-S. A total of six groups of mice were immunized with
either MVA-S or MVTT-S, respectively, through i.m. inocula-
tion. Three mice as one group were given 104, 105, or 106 PFU
of each vaccine. All of the animals were immunized twice at a
three-week interval. Serum samples were collected and subjected
to the neutralization assay two weeks after the second
immunization. As controls, three additional mice received
placebo. As depicted in Fig. 3, since the difference was about
two to three-fold based IC50 values (the 50% inhibitory
concentration), it is likely that MVA-S induced slightly higher
level of Nabs than MVTT-S via i.m. inoculation under the
experimental condition. Two independent immunization exper-
iments were conducted with similar results obtained. Moreover,
there was a clear dose dependency among three MVA-S or
MVTT-S dosing groups. The IC50 values reached over 1:5,000
in the high-dose groups. In contrast, the groups of control mice
did not yield any Nabs.
MVTT-S induced at least over 100-fold higher Nab
response than MVA-S via i.n. or i.o. inoculation
To explore the potential use of MVA-S or MVTT-S as a
mucosal vaccine vector, we further tested these two vaccines in
mice. Seven groups of three BALB/c mice (6-week-old) were
immunized via i.n., i.o., i.m., i.r., i.d., i.p., s.c. routes using an
Figure 2. Virulence of MVTT-S in mice after i.n. inoculation. Groups of six mice were inoculated with MVTT-S, MVA-S or PBS twice at a dose of
106 PFU at a three-week interval. The body weight of animals was measured overtime post inoculation. The average values (6standard error) of body
weight are plotted for each group of animals. The arrow indicates the time of each viral inoculation.
doi:10.1371/journal.pone.0004180.g002
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identical sub-optimal dose (105 PFU), respectively.We chose the sub-
optimal dose in order to avoid the plateau effort of immune
responses under high doses of inoculation in mice [21]. Similar to
i.m. inoculation, all of the animals were immunized twice at a three-
week interval. Serum samples were collected, pooled by equal
volume and subsequently subjected to the neutralization assay two
weeks after the second immunization. As controls, three mice
received placebo. As shown in Fig. 4A, no significant levels of Nabs
were induced in mice that were immunized with MVA-S except for
i.m. and s.c. routes. Less than fifty percent of the virus was
neutralized after the sera were diluted by 1:10 for the rest groups. In
particular, i.n. or i.o. immunization only induced antibodies capable
of neutralizing about 25–30% of virus at 1:10 dilution. In contrast,
MVTT-S induced much higher levels of SARS-CoV-specific Nabs
in mice that were immunized withMVTT-S via the i.n. or i.o. routes
of inoculations (Fig. 4B). Fifty percent of the virus was neutralized
after the sera were diluted by 1:900, which is at least 100-fold better
than that of MVA-S (Fig. 4A). These levels of response based on IC50
were approximately 10-fold higher than that based on i.m.
vaccination when the same dose of inoculum was used (Fig. 4B).
Therefore, MVTT-S is superior to MVA-S once delivered via i.n. or
i.o. routes. During the experiments, the placebo groups of control
mice did not yield any detectable Nabs.
Pre-mucosal exposure to wild-type VTT prevents the
subsequent Nab response using the same route of
vaccination
Considering that pre-existing immunity would interfere with the
effectiveness of live viral vector-based vaccines, we sought to
determine whether this would be the case for MVTT-S and MVA-
S vaccines. To address this issue properly, four groups of four mice
were inoculated with 106 PFU VTT via i.n. and i.o. routes,
respectively. Another four groups of mice received placebo. After
six months of resting, the animals were vaccinated twice with
26106 PFU MVTT-S or MVA-S at a month interval via the
autologous route, and subsequently subjected to the neutralization
assay two weeks after the second immunization. We found that the
pre-mucosal exposure to wild-type VTT had a profound effect on
the effectiveness of MVTT-S and MVA-S vaccines. No neutral-
izing antibody response was detected among the mice that had
previously been exposed to wild-type VTT at the serum dilution of
1:10. Of note, 26106 PFU is the highest dose possible for mucosal
vaccination based on the concentration of our viral stocks. Based
on IC50, placebo mice inoculated with MVTT-S developed 10-
fold (i.o.) to 50-fold (i.n.) higher levels of Nab responses than those
received MVA-S (Fig. 5). Apparently, more than 20-fold of MVA-
S (26106 PFU in Fig. 5) is required to induce similar levels of Nabs
that were elicited by MVTT-S (105 PFU in Fig. 4B) via either i.n.
or i.o. inoculation.
Mucosal vaccination overcomes the pre-existing immune
response induced by the s.c. exposure to wild-type VTT
Due to the suppression of MVTT-S in the previous experiment
as shown in Fig 5, we sought to investigate the situation that
mimics the human smallpox vaccination. In this case, six
experimental groups of four mice were pre-inoculated with 106
Figure 3. Anti-S-specific Nab response in mice vaccinated with
either MVTT-S or MVA-S via the i.m. route. Groups of 3 mice were
injected with MVTT-S (solid symbol) or MVA-S (empty symbol) twice at a
dose of 104 (square), 105 (cycle), 106 (triangle) PFU at a three-week
interval. Sera were collected two weeks after each vaccination. A
pseudotype-based neutralization assay was performed to determine
the level of Nab response. The Y axis stands for the percentage of
inhibition whereas the X axis represents the serum dilution factor. The
dash line indicates the level of 50% of viral inhibition. The neutralization
experiment was repeated twice with similar results obtained. Moreover,
two independent immunization experiments were conducted with
consistent results obtained.
doi:10.1371/journal.pone.0004180.g003
Figure 4. Anti-S-specific Nab response in mice vaccinated with MVA-S (A) or MVTT-S (B) via various routes. Groups of 3 mice were
inoculated with 105 PFU MVTT-S or MVA-S twice at a three-week interval via seven different routes including i.m., i.d., s.c., i.o., i.n., i.r. and i.p. The sera
were collected two weeks after the last injection and subjected to the neutralization assay. The Y axis stands for the percentage of inhibition while
the X axis represents the serum dilution factor. The dash line indicates the level of 50% of viral inhibition. The experiment was repeated twice with
similar results obtained.
doi:10.1371/journal.pone.0004180.g004
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PFU VTT via the s.c. route. Another three groups of mice
received placebo. After six months of resting, one of each
experimental and control groups of animals were vaccinated
twice with 26106 PFU MVA-S or MVTT-S at a month interval
via i.n., i.o. and i.m. routes, respectively. The serum samples were
subsequently subjected to the neutralization assay two weeks after
the second immunization. Interestingly, the s.c. pre-exposure to
VTT had much less interference on the immunogenicity of
MVTT-S when delivered using a heterologous route. After the s.c.
pre-exposure to VTT, i.o. (Fig. 6A) and i.n. (Fig. 6B) were still able
to induce higher levels (20-to-50-fold) of anti-S Nab response when
compared with the i.m. immunization after the second mucosal
vaccination (Fig. 6C). Some reduced responses, however, were
observed for i.o. (,4-fold, Fig. 5A) and i.n. (,10-fold, Fig 5B)
when compared with animals without pre-exposure to VTT. In
contrast, the s.c. pre-exposure to VTT had a profound negative
effect on subsequent MVA-S mucosal vaccinations. Only two i.n.
vaccinations induced some Nabs (Fig. 6E, IC50 = 1:80).
The pre-existing level of anti-VTT Nabs probably affects
the effectiveness of MVA-S and MVTT-S
Considering that MVTT-S induced variable levels of anti-S
Nab when different routes of inoculation were used (Fig. 3), we
sought to determine whether similar effects apply to anti-VTT
vector immune response. To address this issue, we measured the
level of anti-VTT Nabs in mice after three weeks and six months
of VTT vaccination using the FACS-based neutralization assay.
Based on the values of IC50, it was obvious that higher levels of
anti-VTT Nabs were induced via i.n. (1:1384) and i.o. (1:675) than
via s.c. (1:68) inoculations just before the administration of MVA-S
and MVTT-S (Table 1). This finding suggests that these higher
levels of anti-VTT Nabs probably affect the effectiveness of the
subsequent MVA-S and MVTT-S vaccination (Fig. 5). Interest-
Figure 5. Influence of pre–VTT vaccination on the efficacy of
MVTT-S orMVA-S via the same i.n. or i.o. route of immunization,
respectively. Groups of 4 mice were inoculated with 106 PFU VTT via
i.n. or i.o. route, and were subsequently (six months later) injected with
26106 PFU MVTT-S or MVA-S twice at one month interval via the same
routes. No anti-S Nab responses were detected in these animals (flat
lines on the X axis). In contrast, placebo mice, that were previously
given PBS, developed significant levels of anti-S Nab responses after
received two MVTT-S (solid symbol) or MVA-S (empty symbol) injections
via the same i.n. or i.o. route. The Y axis stands for the percentage of
inhibition whereas the X axis represents the serum dilution factor. The
dash line indicates the level of 50% of viral inhibition. The experiment
was repeated twice with similar results obtained.
doi:10.1371/journal.pone.0004180.g005
Figure 6. Influence of the s.c. pre-VTT vaccination on the efficacy of MVTT-S (top panel) or MVA-S (bottom panel) via heterologous
route of immunization. Experimental groups of 4 mice (empty symbol) were inoculated with 106 PFU VTT via the s.c. route, and were subsequently
(six months later) given one (Vac61) or two (Vac62) injections of 26106 PFU MVTT-S or MVA-S twice at one month interval via heterologous routes
including i.o. (A or D), i.n. (B or E) and i.m. (C or F), respectively. Placebo mice (solid symbol), that were previously given PBS, received two injections of
26106 PFU MVTT-S or MVA-S at one month interval via the same routes accordingly. Sera were collected two weeks post the first and the second
inoculation and subjected to the neutralization assay. The Y axis stands for the percentage of inhibition while the X axis represents the serum dilution
factor. The dash line indicates the level of 50% of viral inhibition. The experiment was repeated twice with similar results obtained.
doi:10.1371/journal.pone.0004180.g006
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ingly, the average titer of 1:68 among subcutaneously vaccinated
mice had much less effects on the subsequent i.o. or i.n. MVTT-S
vaccination (Fig. 6A and 6B) when compared with i.m. route
(Fig. 6C). Similar findings were obtained with MVA-S (Fig. 6D, 6E
and 6F). In addition, we determined the anti-S Nab response in
the presence of pre-existing anti-VTT Nabs three weeks after the
first immunization of MVA-S and MVTT-S. We found that i.n.
and i.o. inoculations of MVTT-S were able to induce anti-S Nab
responses (Fig. 6A and 6B). These responses were further
enhanced after the second inoculation of MVTT-S via i.o. (,6-
fold, Fig. 6A) or i.n. (,2-fold, Fig. 6B) routes. The second
immunization also significantly boosted anti-S Nab responses
against MVTT-S via i.m. (Fig. 6C) or MVA-S via i.n. (Fig. 6E)
inoculations, respectively. Therefore, the second MVTT-S
immunization is necessary for boosting Nab response in the
presence of the pre-existing anti-VTT immunity.
Discussion
MVTT offers greater advantage than MVA for inducing high
level of systemic Nab response against SARS-CoV through
mucosal routes of vaccination. Considering that the induction of
Nab is one of the key elements for a successful vaccine, we chose to
use the spike glycoprotein (S) of SARS coronavirus as a test
antigen to understand the immunogenicity profiles of MVA and
MVTT. Another reason to choose S glycoprotein is that we have
previously demonstrated that MVA-S induces protective Nabs that
contributed to the protection of pathogenic SARS-CoV infection
in Chinese macaques [14]. To make a fair comparison, the S gene
of SARS-CoV was constructed in the equivalent genomic location
of two live vectors (Fig. 1). We found that MVA-S induced 2-3-fold
higher levels of Nab response than MVTT-S in mice via the i.m.
route of inoculation using sub-optimal doses (Fig. 3). This finding
suggests that it is possible that the replicating MVTT-S does not
seem to offer much advantage when delivered intramuscularly, a
systemic way of vaccination. We noticed that the advantage for
MVA-S i.m. immunization reduced when a higher dose of vaccine
was tested (Fig. 6C and 6F). This observation suggests that MVA-S
has probably reached the plateau of Nab response given its non-
replicating nature. Another possibility is related to the experimen-
tal setting because there was a long resting period (six months)
after the animals received the placebo inoculation (Fig. 6). We,
however, found that the i.n. or i.o. inoculation of MVTT-S
induced the highest levels of Nab response which was over at least
100-fold higher than those of MVA-S using a sub-optimal dose
(105 PFU) (Fig. 4). Moreover, we demonstrated that a minimum of
20-fold or more of MVA-S (26106 PFU in Fig. 5) is required in
order to induce similar levels of Nabs that were elicited by 105
PFU of MVTT-S (Fig. 4B) via either i.n. or i.o. inoculation. These
findings are new and suggest that a much higher minimal dose is
required for MVA-S to be immunogenic via mucosal vaccination.
Similar results have not been reported by comparing other
replicating vaccinia strains with MVA for inducing Nab responses
[9,43]. Since these levels of Nab response are 10-fold higher than
those induced via the i.m. route, our findings suggest that MVTT-
S is superior to MVA-S when delivered via the i.n. or i.o. route.
There are some possibilities to explain our findings. First, MVTT-
S may target the mucosa-associated antigen presenting cells more
efficiently. Second, the replication competency of MVTT-S may
have growth advantage in mucosal tissues in providing continuous
immune stimulation. Third, MVTT-S may contain mucosa-
specific immune regulatory proteins which MVA-S does not have.
Further studies will be needed to determine the underlined
mechanism of MVTT-S-mediated mucosal vaccination. Our data
provide direct evidence that the use of different vaccinia vectors
may produce significantly different immunogenicity profiles for an
identical test antigen. Our MVTT system may potentially assist
some weak viral immunogens (e.g HIV-1 gp140) for inducing
better Nab responses [21]. To this end, the intranasal delivery of a
VTT-based vaccine, when used in combination with a DNA,
induced strong HIV-1 specific immune responses in a recent small
animal study [20]. Since VTT strains may come from different
sources and display distinct in vivo toxicity and immunogenicity
profiles, vectors aiming for clinical use should be carefully studied
[11].
Mucosal vaccination overcomes the pre-existing immunity that
was induced through s.c. route of vaccination by wild-type VTT.
Pre-existing immunity is often the issue which is related to the
effectiveness of live viral vector-based vaccines [37,44]. It is also a
critical issue for the clinical development of a vaccinia-based
vaccine. Consistent with previous findings on other vaccinia-based
vectors, we found that pre-mucosal exposure to wild-type VTT
had a profound effect in preventing the subsequent Nab response
using the same route of vaccination by MVTT-S (Fig. 5). In
contrast, if the pre-exposure to wild-type VTT was through the s.c.
route, mucosal vaccination via either i.n. or i.o. inoculation was
able to overcome the pre-existing immune response to the vector,
and to induce high level of anti-S Nabs (Fig. 6A and 6B). Since the
latter situation mimics the conventional smallpox vaccination, our
data have critical implications for millions of people who had been
historically vaccinated with VTT through skin scarification. In
support of this notion, we found that most of VTT-vaccinated
Chinese people only maintain low levels of Nabs (,1:60, data not
shown). Mucosal vaccination, as a non-invasive or a needless
procedure, has great implications for the large scale of vaccination
programs in developing countries especially for nations with huge
populations. In addition, the replication competent nature of
MVTT permits a minimized dose of each vaccination and reduces
the manufacture burden, which makes MVTT-based vaccine
become cost effective. MVTT, therefore, is an attractive
attenuated replicating-competent vaccinia vector for mucosal
vaccination. Other approaches however for assisting mucosal
delivery of MVTT-based vaccine should be further studied to
overcome the anti-vector pre-existing immunity [44].
Mucosal vaccination may offer great advantage for inducing
protective immune responses at the mucosal sites of viral
transmission. Consistent with the anti-S Nab response induced
by MVTT-S, the i.n. or i.o. inoculation of wt-VTT also induced
much higher levels of Nab response against the viral vector than
that of the s.c. vaccination (Table 1). In fact, this anti-VTT
response probably played a critical role in eliminating the
subsequent inoculation of MVTT-S through the autologous route
or in preventing viral dissemination, and therefore prevented the
induction of Nab response against S glycoprotein. On one hand,
the data suggest that both VTT and MVTT probably offer great
advantage for inducing protective Nab responses at the mucosal
Table 1. The titer of anti-VTT neutralizing antibody (IC50).
Route Day 21* Day180
s.c. ,20 1:68
i.n. 1:540 1:1384
i.o. 1:500 1:675
*indicates the date of sampling after various routes of vaccination.
IC50 stands for the antibody titer when 50% of virus was neutralized.
doi:10.1371/journal.pone.0004180.t001
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sites of viral transmission. On the other hand, the data highlight
the importance of the proper selection of vaccination routes for
VTT- or MVTT-based vaccine vectors. Having said so, we do not
recommend the use of VTT as a vaccine vector for mucosal
vaccination due to its in vivo toxicity and pathogenicity [11,38].
Unexpectedly, we were not able to detect anti-S neutralizing IgA
activity (1:10–1:20) in the saliva of animals vaccinated with either
MVA-S or MVTT-S via any route of vaccination. One possibility
is that both MVA-S and MVTT-S have dominantly induced
neutralizing IgG responses to block viral transmission and
dissemination [11,38]. We also evaluated supernatants from
homogenates of lung and intestines. Due to technical difficulties
to exclude Nab contamination from the blood, the results are not
presented here. Further careful studies will be needed to determine
whether MVTT system would offer advantages for inducing Nab
and cell mediated immune responses at mucosal sites. Other viral
antigens (e.g. HIV-1) should be also tested to determine whether
or not our findings are antigen-dependent.
In conclusion, our replication-competent vaccinia vector
MVTT is superior to MVA for inducing high levels of neutralizing
antibody via mucosal vaccination. Moreover, the mucosal
vaccination may potentially offer significant advantages to
overcome the pre-existing anti-VV immunity for people who
previously received smallpox vaccination. MVTT is therefore an
attractive live viral vector for the development of future mucosal
vaccines.
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